144 related articles for article (PubMed ID: 26401102)
1. Physiologic Doses of Ascorbic Acid Increase Arsenic Trioxide Toxicity in Human Jurkat -T Lymphoma Cells.
Yedjou CG; Byrd R; Allen L; Tchounwou PB
Met Ions Biol Med; 2011; 11():236-241. PubMed ID: 26401102
[TBL] [Abstract][Full Text] [Related]
2. ASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.
Yedjou CG; Brown E; Rogers C; Tchounwou PB
Met Ions Biol Med; 2008; 10():413-418. PubMed ID: 26549974
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells.
Yedjou CG; Rogers C; Brown E; Tchounwou PB
J Biochem Mol Toxicol; 2008; 22(2):85-92. PubMed ID: 18418892
[TBL] [Abstract][Full Text] [Related]
4. Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia.
Yedjou C; Thuisseu L; Tchounwou C; Gomes M; Howard C; Tchounwou P
Arch Drug Inf; 2009 Dec; 2(4):59-65. PubMed ID: 20098508
[TBL] [Abstract][Full Text] [Related]
5. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells.
Sumi D; Suzukawa K; Himeno S
Life Sci; 2016 Mar; 149():42-50. PubMed ID: 26892147
[TBL] [Abstract][Full Text] [Related]
7. OXIDATIVE STRESS IN HUMAN LEUKEMIA (HL-60), HUMAN LIVER CARCINOMA (HepG2), AND HUMAN (JURKAT-T) CELLS EXPOSED TO ARSENIC TRIOXIDE.
Yedjou CG; Tchounwou PB
Met Ions Biol Med; 2006; 9():298-303. PubMed ID: 26435679
[TBL] [Abstract][Full Text] [Related]
8. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
[TBL] [Abstract][Full Text] [Related]
11. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
13. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
14. Ascorbic Acid Sensitizes Colorectal Carcinoma to the Cytotoxicity of Arsenic Trioxide
Tian W; Wang Z; Tang NN; Li JT; Liu Y; Chu WF; Yang BF
Front Pharmacol; 2020; 11():123. PubMed ID: 32153415
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
16. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
Aldoss I; Mark L; Vrona J; Ramezani L; Weitz I; Mohrbacher AM; Douer D
Ann Hematol; 2014 Nov; 93(11):1839-43. PubMed ID: 24906216
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
18. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L
Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells.
Rogers CS; Yedjou CG; Sutton DJ; Tchounwou PB
Exp Hematol Oncol; 2014 Mar; 3(1):9. PubMed ID: 24661615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
